CEO and CFO appointments
Chief Executive Officer and Chief Financial Officer appointments
London, UK, 6 November 2025 - The Board of Directors of Convatec is pleased to announce the appointments of Jonny Mason as Chief Executive Officer and Fiona Ryder as Chief Financial Officer, with immediate effect.
Dr John McAdam, Chair of the Board of Directors, said:
"Since joining the business in 2022 as CFO, Jonny has demonstrated exceptional leadership and is highly regarded for his contribution to Convatec's successful turnaround. Jonny has extensive experience leading publicly listed and international businesses. The Board is confident in his ability to build on the successful transformation led by Karim over the last 6 years, and enable Convatec to deliver its full potential.
Fiona's appointment demonstrates the strength of internal talent that Convatec has built. She is a seasoned finance leader with a strong track record in global businesses, having led finance functions while based in the UK, US and Singapore. She has played a pivotal role in delivering Convatec's focus on simplification and productivity, has been fundamental to the success of the FISBE strategy.
I look forward to working with Jonny and Fiona to deliver value for all our stakeholders, making a real difference to the lives of people relying on Convatec's products, services and solutions."
Jonny Mason, Chief Executive Officer, said:
"Convatec is a brilliant business, full of talented colleagues, making a real difference to the lives of millions of people around the world. As we accelerate our growth and scale up the richest innovation pipeline in Convatec's history, we have significant potential ahead of us. Above all else, we will remain focused on delivering our vision, pioneering trusted medical solutions to improve the lives we touch. As my close colleague and friend Karim often said, Convatec's best days are ahead of us, and I'm determined to prove that he was right."
Fiona Ryder, Chief Financial Officer, said:
"I am very pleased for the opportunity to continue to build on what we have achieved through Convatec's turnaround and to support our teams to realise Convatec's full potential. The opportunities ahead of us are substantial. I'm looking forward to continuing to work with Jonny and the team to deliver our plans for the benefit of all our stakeholders."
Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025. Fiona Ryder joined Convatec on 3 January 2022 as Group Financial Controller and became Interim CFO on 4 August 2025. Fiona will become a Director of the Company from 6 November 2025.
Notes
There is no other information to be disclosed under UK Listing Rule 6.4.8 R in relation to the appointment of Fiona Ryder.
Jonny Mason and Fiona Ryder will be paid in accordance with the Company's Directors' Remuneration Policy. Full details of Jonny Mason's and Fiona Ryder's remuneration arrangements will be disclosed in the Directors' Remuneration Report for 2025.
Contacts
Media: mediarelations@convatec.com
Analysts & investors: ir@convatec.com
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 hours ago Oxford Nanopore Technologies
- 5 hours ago AVI Global Trust
- 6 hours ago LSL Property Services
- 6 hours ago Bluebird Merchant Ventures (DI)
- 6 hours ago Power Probe PLC